Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00559429
What this trial is testing

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 13
Testing effectiveness (Phase 2)Study completedNCT00005857
What this trial is testing

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Who this might be right for
Prostate Cancer
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT00541281
What this trial is testing

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Who this might be right for
Hormone Resistant Prostate CancerMetastatic Prostate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 150
Testing effectiveness (Phase 2)Study completedNCT00052845
What this trial is testing

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 80
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Large-scale testing (Phase 3)Active Not RecruitingNCT02257736
What this trial is testing

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms
Aragon Pharmaceuticals, Inc. 982
Early research (Phase 1)Study completedNCT01723475
What this trial is testing

First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Bayer 47
Testing effectiveness (Phase 2)Looking for participantsNCT07451795
What this trial is testing

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Who this might be right for
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University 66
Testing effectiveness (Phase 2)Study completedNCT01796028
What this trial is testing

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Centre Antoine Lacassagne 100
Testing effectiveness (Phase 2)Study completedNCT01046916
What this trial is testing

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 38
Early research (Phase 1)Not Yet RecruitingNCT07682649
What this trial is testing

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
University of Michigan Rogel Cancer Center 20
Not applicableStudy completedNCT05701007
What this trial is testing

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer 1,083
Early research (Phase 1)Study completedNCT03805594
What this trial is testing

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+4 more
University of California, San Francisco 43
Not applicableStudy completedNCT02907372
What this trial is testing

Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (CRPCa)
Centre Francois Baclesse 163
Early research (Phase 1)Ended earlyNCT04421222
What this trial is testing

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
ESSA Pharmaceuticals 71
Testing effectiveness (Phase 2)Study completedNCT02788773
What this trial is testing

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 52
Not applicableActive Not RecruitingNCT04024475
What this trial is testing

Prostate Cancer Biobank

Who this might be right for
Prostatic Neoplasms
Swiss Cancer Institute 1,323
Very early researchStudy completedNCT03275857
What this trial is testing

Cisplatin in Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University of Rochester 12
Early research (Phase 1)Study completedNCT01338831
What this trial is testing

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Who this might be right for
Castration-resistant Prostate CancerMetastatic Breast CancerUterine Leiomyoma
Novartis Pharmaceuticals 73
Testing effectiveness (Phase 2)Active Not RecruitingNCT01688492
What this trial is testing

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 54
Next Page